News
The initiative will provide practical insights into understanding of obesity pathophysiology and its management.
Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program
Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...
Morgans healthcare and life sciences expert Iain Wilkie fills in for Scott Power this week, covering what the health movers ...
An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...
Eli Lilly and Company (NYSE:LLY) is one of the high-margin pharma stocks to buy now. Eli Lilly and Company (NYSE:LLY) is set ...
A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.
Opinion
GLP-1s, Personalization, and Big Pharma Power Plays: What’s Really at Stake in the Eli Lilly LawsuitThis lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.
Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.
NDTV Profit on MSN6d
Cipla To Take On Eli Lilly, Novo Nordisk With Entry Into India's Weigh-Loss Drug SectorCipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and Danish firm Novo Nordisk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback